Publication:
HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests

dc.contributor.authorMuñoz-Chimeno, Milagros
dc.contributor.authorValencia, Jorge
dc.contributor.authorRodriguez-Recio, Alvaro
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorGarcia-Lugo, Maira Alejandra
dc.contributor.authorManzano, Samuel
dc.contributor.authorRodriguez-Paredes, Vanessa
dc.contributor.authorFernandez, Beatriz
dc.contributor.authorMorago, Lucia
dc.contributor.authorCasado, Concepcion
dc.contributor.authorAvellón, Ana
dc.contributor.authorRyan, Pablo
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderAbbottes_ES
dc.date.accessioned2023-08-24T09:47:03Z
dc.date.available2023-08-24T09:47:03Z
dc.date.issued2023-05-09
dc.description.abstractPoint of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis study was supported by the research contract MVP128/21 ISCIII-Abbott.es_ES
dc.format.number1es_ES
dc.format.page7554es_ES
dc.format.volume13es_ES
dc.identifier.citationSci Rep. 2023 May 9;13(1):7554.es_ES
dc.identifier.doi10.1038/s41598-023-33925-2es_ES
dc.identifier.e-issn2045-2322es_ES
dc.identifier.journalScientific reportses_ES
dc.identifier.pubmedID37160925es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16336
dc.language.isoenges_ES
dc.publisherNature Publishing Groupes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MVP128/21es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-023-33925-2es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHepatitis Ces_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHumanses_ES
dc.subject.meshHepaciviruses_ES
dc.subject.meshHepatitis B viruses_ES
dc.subject.meshHIVes_ES
dc.subject.meshHepatitis B Surface Antigenses_ES
dc.titleHCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory testses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication9346d125-bed0-41c7-9be3-25e5e0d652c3
relation.isAuthorOfPublication7e2617cb-3fdd-4249-8c21-56c2b399cc90
relation.isAuthorOfPublicationf0b66a6a-5faf-427e-8558-92b0ea126b7c
relation.isAuthorOfPublicationd3b3423e-9a52-4673-8a2c-f04ea049c018
relation.isAuthorOfPublication1b20dfe3-5a74-4fdc-8d41-930ccd71bf26
relation.isAuthorOfPublication7e48a263-54c3-4de0-81e7-f7446c918f2d
relation.isAuthorOfPublication392ba1dd-467b-4d9e-a8f5-b1195fbaf532
relation.isAuthorOfPublication.latestForDiscovery9346d125-bed0-41c7-9be3-25e5e0d652c3

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
HCV_HIV_HBV_RapidTest.2023.pdf
Size:
944.12 KB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Suplementary_HCV_HIV_HBV_RapidTest.2023.pdf
Size:
431.49 KB
Format:
Adobe Portable Document Format
Description:
Supplementary material